Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders. Trophos was founded in 1999 in Marseille by three scientists, Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus and two entrepreneurs, Antoine Beret and Michel Delaage. Trophos' lead compound was TRO19622 / olesoxime. Olesoxime is a mitochondrial targeted compound, which is a member of a new class of therapeutic agents aimed at bringing significant therapeutic benefit to patients suffering from devastating neurological diseases. Spinal Muscular Atrophy (SMA) is an autosomal recessive genetic disease that affects the motor neurons of the voluntary muscles used for activities such as crawling, walk